ClinicalTrials.gg
Not yet recruitingNCT07505511VISUALIZE-PROUpdated Apr 1, 2026

Visualization of the Effects of Guideline-directed Medical Therapy (GDMT) on Improving Adherence and Quality of Life in Heart Failure With Reduced Ejection Fraction (HFrEF)

An Early Phase 1 interventional study of Intervention: Visual Adherence Support (VISUALIZE-Pro) in Adherence, Medication, Adherence, Treatment and Heart Failure, sponsored by University of Giessen. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-01.

Sponsored by University of Giessen · Early Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Heart failure with reduced ejection fraction (HFrEF) remains a major public health challenge with substantial morbidity and mortality despite the availability of effective guideline-directed medical therapy (GDMT). Although four major drug classes have been shown to significantly improve survival and reduce hospitalizations, real-world implementation remains suboptimal. In addition to underutilization by healthcare providers, poor medication adherence among patients-reported to range between 29% and 63%-represents a critical barrier to achieving optimal therapeutic benefit.

The Visualize-Pro study is a prospective, exploratory pilot study designed to evaluate a simple, patient-centered intervention aimed at improving medication adherence in patients with HFrEF. The intervention consists of patient-friendly graphical visualizations illustrating the survival benefits and risk reduction associated with optimal heart failure therapy. These materials are designed to enhance patient understanding, motivation, and engagement with prescribed treatments.

To objectively assess medication adherence, this study incorporates therapeutic drug monitoring (TDM) as a gold standard method, in addition to established patient-reported outcome measures such as quality of life and adherence questionnaires. Blood samples will be collected at predefined study visits, and drug levels (or their metabolites) will be analyzed in collaboration with a specialized laboratory to quantify adherence.

Participants will be followed over a predefined study period with serial assessments at scheduled visits.

The primary objective is to evaluate the feasibility and preliminary effectiveness of the intervention in improving medication adherence. Secondary objectives include assessing changes in patient-reported outcomes and exploring associations between adherence and clinical parameters.

As a pilot study, the results are intended to inform the design of a future large-scale, multicenter trial. Ultimately, this approach aims to provide a scalable and low-threshold strategy to improve adherence to life-saving therapies in heart failure, thereby contributing to reduced morbidity and mortality in this high-risk population.

02

Conditions studied

  • Adherence, Medication
  • Adherence, Treatment
  • Heart Failure
03

In context

Medication Adherence

943 studies on the registry are indexed under Medication Adherence; 162 are open to participants now.

This study's planned enrollment of 100 is below the median of 120 across 773 interventional studies indexed under Medication Adherence.

Browse Medication Adherence studies →

Lead sponsor

University of Giessen is the lead sponsor of 95 studies on the registry; 22 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years
  • Diagnosis of heart failure with reduced (HFrEF) (left ventricular ejection fraction ≤40%)
  • Indication for guideline-directed medical therapy (GDMT) for heart failure
  • Stable clinical condition at the time of enrollment
  • Ability to understand the study procedures and provide written

Exclusion criteria

Exclusion Criteria:

  • Acute decompensated heart failure requiring immediate hospitalization
  • Severe cognitive impairment or inability to understand study-related information
  • \<6 months due to non-cardiac comorbidities
  • Participation in another interventional clinical trial that may interfere with this study
  • to prescribed heart failure medications
  • Any condition that, in the investigator's judgment, precludes safe participation in the study
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Other
    Intervention: Visual Adherence Support (VISUALIZE-Pro)

    Participants receive a patient-centered adherence intervention using graphical visualizations to illustrate the survival benefits and risk reduction associated with guideline-directed medical therapy (GDMT) for heart failure. The VISUALIZE-Pro approach aims to improve patients' understanding of their treatment, enhance motivation, and promote medication adherence. Adherence is objectively assessed using therapeutic drug monitoring (TDM) at predefined study visits and complemented by patient-reported outcomes and clinical assessments.

    Behavioral: Intervention: Visual Adherence Support (VISUALIZE-Pro)

Interventions

  • BehavioralIntervention: Visual Adherence Support (VISUALIZE-Pro)

    Participants receive a patient-centered adherence intervention using graphical visualizations to illustrate the survival benefits and risk reduction associated with guideline-directed medical therapy (GDMT) for heart failure. The VISUALIZE-Pro approach aims to improve patients' understanding of their treatment, enhance motivation, and promote medication adherence. Adherence is objectively assessed using therapeutic drug monitoring (TDM) at predefined study visits and complemented by patient-reported outcomes and clinical assessments.

06

What researchers measure

Primary outcomes

  1. Medication adherence assessed by therapeutic drug monitoring (TDM)

    Medication adherence will be objectively assessed using therapeutic drug monitoring (TDM) by measuring serum concentrations of prescribed heart failure medications (or their metabolites) at predefined study visits. Adherence is defined as detectable drug levels within the expected therapeutic range based on dosing information.

    Time frame: At predefined study visits (e.g., baseline and follow-up visits up to 3/6months)

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Mar 2026; primary completion for Aug 2027, 17 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 17, 2026
First posted
Apr 1, 2026
StartEst.
Mar 1, 2026
Primary completionEst.
Aug 1, 2027
CompletionEst.
Mar 1, 2028
Last update
Apr 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07505511
Lead sponsor
University of Giessen
Collaborators
Kruse Johannes, Florian Blachutzik, Andreas Rieth
Responsible party
Jamschid Sedighi (Dr. med., University of Giessen) — Principal investigator
First posted
Apr 1, 2026
Start date
Mar 1, 2026 (estimated)
Primary completion
Aug 1, 2027 (estimated)
Completion
Mar 1, 2028 (estimated)
Last update
Apr 1, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion